Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo
Article Category: Original article
Published Online: Apr 30, 2024
Page range: 61 - 68
DOI: https://doi.org/10.2478/abm-2024-0009
Keywords
© 2024 Shenglin Lu et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Background
The early diagnosis and treatment of cholangiocarcinoma may benefit from specific tumor markers to be used in clinical practice.
Objectives
To investigate whether the pGCsiRNA-vascular endothelial growth factor (VEGF) can affect the onset and progression of cholangiocarcinoma and its possible mechanism using the targeted therapy of nude mouse model of cholangiocarcinoma with attenuated
Methods
The nude mouse model of cholangiocarcinoma was established by tail vein injection of QBC939 cells and given attenuated
Results
The tumor volume and weight of the pGCsiRNA-VEGF group were significantly smaller than those of the mock and the si-scramble groups (
Conclusions
In vivo silencing of VEGF can affect cell survival and inhibit cell migration, invasion, and development, probably by enhancing apoptosis and inhibiting the expressions of MMP2 and MMP9.